Market Cap
$2.2B
WGS
GeneDx Holdings Corp.
$72.36 ▲ +1.97%
Prev close $70.96Market cap$2.2B
ConsensusStrong Buy
12-mo target$93.50 (+29.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on WGS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (92%)
Inst. Holders
50 funds
Inst. Value
$1.5B
Inst. Activity
29 buys / 21 sells
Insider Activity
$25.1M buy / $3.0M sell
Insider Net $
$22.1M
Social Sentiment
58° Warm
SEC Reports
10
Press Releases
1
Price chart 30d -16.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Short Volume: WGS — 55.7% short (0.4M / 0.7M)
Short: 378,489 | Exempt: 6,347 | TRF Vol: 679,629 | Short Ratio: 55.7% | Off-exchange volume (dark p
Sep 17, 2026 Insider
Fuchs Thomas acquired via exercise 1,146 shares
Director
Sep 16, 2026 Insider
Feeley Kevin sold 1,079 shares
CHIEF FINANCIAL OFFICER @ $99.00 ($106.8K)
Sep 16, 2026 Insider
Sep 12, 2026 SEC Feeley Kevin sold 586 shares
CHIEF FINANCIAL OFFICER @ $94.26 ($55.2K)
GeneDx Holdings CEO Katherine Stueland and CFO Kevin Feeley sold a combined $419K in open-market shares on September 9,
CLUSTER — Impact 2/10
Officer and Director Katherine Stueland filed a Form 144 notice of intent to sell 14,243 shares of GeneDx Holdings Corp.
144 — Impact 2/10
Robbins LLP announced a securities class action lawsuit against GeneDx Holdings Corp. (WGS) alleging the company misled
Impact 7/10
A securities class action lawsuit has been filed against GeneDx Holdings (WGS) alleging the company concealed material a
PRESS-RELEASE — Impact 7/10
Analyst ratings buy % +8.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
92% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 1, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 4, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Aug 4, 2026 | BTIG | REITERATE | Buy | 53% |
| Jun 29, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jun 23, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| May 5, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| May 5, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| May 5, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| May 5, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Apr 20, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Aug 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jul 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Jun 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 8 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Price targets
Where 8 covering analysts think WGS trades over the next 12 months.
$93.50 +29.2% upside Strong Buy
Current$72.36 Low$83.00 Median$92.50 High$103.00 8 analysts
$83.00$103.00
Analyst rating Strong Buy· 1.1/5 as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
58°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 3 bearish, 0 mixed, 4 neutral · avg impact 4.6/10.Plus 1 press releases.
NEUTRALCLUSTER2/10
GeneDx Holdings CEO Katherine Stueland and CFO Kevin Feeley sold a combined $419K in open-market sha
Sep 12, 2026
NEUTRAL1442/10
Officer and Director Katherine Stueland filed a Form 144 notice of intent to sell 14,243 shares of G
Sep 1, 2026
BEARISHPRESS-RELEASE7/10
A securities class action lawsuit has been filed against GeneDx Holdings (WGS) alleging the company
Jul 23, 2026
NEUTRAL8-K3/10
GeneDx appointed Mark Gardner as President, effective June 15, 2026, to oversee lab and commercial o
Jun 16, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
short_volume
Short Volume: WGS — 55.7% short (0.4M / 0.7M)
Short: 378,489 | Exempt: 6,347 | TRF Vol: 679,629 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: WGS — 74.6% short (0.5M / 0.6M)
Short: 450,595 | Exempt: 192 | TRF Vol: 603,615 | Short Ratio: 74.6% | Off-exchange volume (dark pool + OTC)
Aug 4, 2026
short_volume
Short Volume: WGS — 61.6% short (0.8M / 1.2M)
Short: 763,895 | Exempt: 112 | TRF Vol: 1,239,294 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Aug 3, 2026
other
DEADLINE TODAY: GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against GeneDx Holdings Corp. ("GeneDx" or "th
Aug 3, 2026
other
DEADLINE TODAY: GeneDx Holdings Corp. Investor Alert: Contact SBS by August 3, 2026 for Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Aug. 3, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class act
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.07 | $0.07–$0.08 | -85.1% | +0.5% | 1↑ 7↓ | $0.1B | 7 |
| Next Q | $0.32 | $0.21–$0.50 | 128.6% | +1.6% | 2↑ 6↓ | $0.1B | 7 |
| Current FY | $0.13 | $0.02–$0.32 | -90.6% | +3.1% | 3↑ 2↓ | $0.5B | 7 |
| Next FY | $1.20 | $0.44–$2.00 | 812.0% | +2.6% | 5↑ 3↓ | $0.6B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.073 | — |
| 7d ago | $0.072 | +0.000 |
| 30d ago | $0.072 | +0.000 |
| 60d ago | $0.102 | -0.030 |
| 90d ago | $0.115 | -0.042 |
Institutional ownership
Which big funds own WGS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.5B total value (22,134,525 shares) as of 2026-Q2. Top holders: Corvex, BlackRock,, GOLDMAN. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Corvex Management LP | 4,784,570 | $328.5M | 21.6% | ADD +48.2% |
| BlackRock, Inc. | 1,706,239 | $117.1M | 7.7% | — |
| GOLDMAN SACHS GROUP INC | 1,669,441 | $114.6M | 7.5% | ADD +25.1% |
| ARK Investment Management LLC | 1,610,189 | $110.5M | 7.3% | — |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1,400,653 | $96.2M | 6.3% | ADD +80.7% |
| MORGAN STANLEY | 988,297 | $67.8M | 4.5% | ADD +85.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 879,003 | $60.3M | 4.0% | — |
| CITADEL ADVISORS LLC | 865,462 | $59.4M | 3.9% | ADD +33.7% |
| Sumitomo Mitsui Trust Group, Inc. | 666,581 | $45.8M | 3.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 552,125 | $37.9M | 2.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| Corvex Management LP | ADD | 3,228,149 | 4,784,570 | +48.2% | $328.5M |
| GOLDMAN SACHS GROUP INC | ADD | 1,334,980 | 1,669,441 | +25.1% | $114.6M |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | ADD | 775,269 | 1,400,653 | +80.7% | $96.2M |
| MORGAN STANLEY | ADD | 532,235 | 988,297 | +85.7% | $67.8M |
| CITADEL ADVISORS LLC | ADD | 647,401 | 865,462 | +33.7% | $59.4M |
| Aberdeen Group plc | ADD | 230,096 | 457,201 | +98.7% | $31.4M |
| BANK OF AMERICA CORP /DE/ | ADD | 234,606 | 346,211 | +47.6% | $23.8M |
| Assenagon Asset Management S.A. | DOUBLED | 95,128 | 303,433 | +219.0% | $20.8M |
| NORGES BANK | NEW | — | 273,100 | — | $18.7M |
| UBS Group AG | DOUBLED | 50,825 | 208,663 | +310.6% | $14.3M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
11 insiders, 50 transactions. Net $22.1M — $25.1M bought, $3.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Fuchs Thomas | Director | EXERCISE | 1,146 | — | — |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 1,079 | $99.00 | $106.8K |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 586 | $94.26 | $55.2K |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 52 | $95.41 | $5.0K |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | EXERCISE | 7,197 | — | — |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 1,470 | $98.27 | $144.5K |
| Sep 16, 2026 | Feeley Kevin | CHIEF FINANCIAL OFFICER | SELL | 541 | $96.90 | $52.4K |
| Sep 16, 2026 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | EXERCISE | 18,750 | — | — |
| Sep 16, 2026 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 1,648 | $94.26 | $155.3K |
| Sep 16, 2026 | Stueland Katherine | CHIEF EXECUTIVE OFFICER | SELL | 148 | $95.41 | $14.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for WGS.
Shares short
5,884,765
Settlement Sep 15, 2026
Change vs prior
-1.9%
Semi-monthly cycle
Days to cover
12.1
At avg daily volume
Of shares outstanding
≈19.7%
Estimate — not % of float
All WGS filing & press-release reports (11)
- CLUSTER reportSep 12, 2026
- 144 reportSep 1, 2026
- PRESS-RELEASE reportJul 27, 2026
- PRESS-RELEASE reportJul 23, 2026
- 8-K reportJun 16, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportJun 8, 2026
- CLUSTER reportMay 20, 2026
- CLUSTER reportMar 30, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 5, 2026